A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Liafensine (Primary)
- Indications Depression
- Focus Therapeutic Use
- Acronyms ENLIGHTEN
- Sponsors Denovo Biopharma
- 28 May 2024 According to a Denovo Biopharma LLC media release, results will be presented at two sessions at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, FL
- 03 Apr 2024 Status changed from recruiting to completed.
- 03 Apr 2024 Primary endpoint has been met. (Change in MADRS Total Score), according to Denovo Biopharma media.